TRIBEKA is a consortium between two world leading academic and research centres for dementia prevention. The consortium is set up to understand the specific brain changes that take place during the middle age of an individual’s life course – we know that it is during the middle age where the earliest phases of neurodegenerative diseases start. TRIBEKA will generate an open access neuroimaging platform that will use novel techniques to identify these very early preclinical changes and pre-amyloid deposition in the Alzheimer’s disease continuum and other neurodegenerative conditions.
The TRIBEKA platform is designed to deliver the largest and best characterised data for understanding neurodegenerative disease and related clinical models in mid-life that is ever assembled globally. The project will include a total sample size of more than 1,000 subjects.
The TRIBEKA imaging platform will involve younger, middle aged participants, and therefore bring empirical data and knowledge to an earlier stage of the life course. The large scale projects TRIBEKA is aligned with already collect vast amounts of data on risk factors from people in their mid-life. This includes genetic data, cognition, behavioral, clinical and neuropsychiatric outcomes, as well as blood, saliva, CSF and urine samples for biomarker analysis and discovery.
The consortium aims to offer the academic and drug development community evidence upon which to base drug development and other interventions. These drug developments will benefit from new insights, biomarker discovery, patient stratification and novel clinical and neuropsychological outcome measures. The TRIBEKA platform will include a total sample size of more than 1,000 subjects. These individuals are followed longitudinally to incorporate any changes in outcomes into the modeling of how neurodegenerative diseases develop starting in the earliest stages. The TRIBEKA participants might also be offered the opportunity to be included in interventional programs like EPAD, which TRIBEKA is closely aligned to.
TRIBEKA will therefore be a facilitator for evidence based interventions for dementia prevention, with the ultimate purpose of playing a significant part in the advancement of neuroscience to secure prevention of dementia by 2025.